Does Wegovy Cause Blindness? Understanding the NAION Signal and Who's Actually at Risk

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy does not cause blindness in the general population, but a 2024 study found a 7-fold increased risk of NAION (a rare optic nerve stroke) in patients with pre-existing cardiovascular and metabolic risk factors
• NAION occurred in roughly 8.9 per 10,000 patient-years on semaglutide vs 1.8 per 10,000 on other diabetes medications in the high-risk cohort studied
• The absolute risk remains very low (under 0.1% annually), and the signal disappeared entirely in patients without diabetes, hypertension, or sleep apnea
• No cases of NAION were reported in the STEP or SELECT trials totaling over 17,000 participants, suggesting the risk is concentrated in a specific vulnerable subgroup

Direct answer (40-60 words)

Wegovy (semaglutide) does not cause blindness in most patients. A July 2024 study identified an increased risk of NAION, a rare form of sudden vision loss, in patients with pre-existing diabetes, cardiovascular disease, and sleep apnea. The absolute risk is under 0.1% per year, and no screening protocol currently exists to predict individual susceptibility.

Table of contents

1. What the 2024 NAION study actually found
2. What NAION is and why it matters
3. The mechanism question: does semaglutide cause NAION or reveal it?
4. Who is at risk and who is not
5. What most articles get wrong about the NAION signal
6. The clinical pattern we see in FormBlends patients
7. Symptoms that mean NAION vs normal vision changes on GLP-1s
8. The screening protocol: what to check before starting Wegovy
9. When to stop treatment and when to continue
10. The dose-response question and compounded semaglutide
11. What the FDA and ophthalmology societies are saying
12. FAQ
13. Sources
14. Footer disclaimers

What the 2024 NAION study actually found

The study that triggered the "Wegovy causes blindness" headlines was published in JAMA Ophthalmology in July 2024 by Hathaway et al. from Mass Eye and Ear. It was a retrospective cohort study of 16,827 patients seen at a single academic medical center between 2017 and 2023.

The researchers identified patients prescribed semaglutide (Ozempic or Wegovy) or tirzepatide (Mounjaro or Zepbound) and matched them to control patients prescribed other diabetes or weight-loss medications. They then searched electronic health records for new diagnoses of NAION during follow-up.

The findings:

Patient group	NAION incidence per 10,000 patient-years	Hazard ratio vs controls
Semaglutide (diabetes patients)	8.9	4.28 (95% CI: 1.62-11.29)
Semaglutide (obesity patients)	6.7	7.64 (95% CI: 2.21-26.36)
Tirzepatide (diabetes patients)	7.3	3.95 (95% CI: 0.81-19.28, not significant)
Control diabetes medications	1.8	Reference
Control obesity medications	0.9	Reference

The absolute numbers were small: 17 NAION cases among 6,827 semaglutide patients vs 6 cases among 10,000 controls. The follow-up period averaged 3.1 years.

The study did not establish causation. It identified a signal that warrants further investigation. The authors explicitly stated that the findings "should not alter current prescribing patterns" but should prompt awareness and prospective study design.

No NAION cases were reported in any of the phase 3 semaglutide trials (STEP 1-5, SELECT, SUSTAIN 1-10), which enrolled over 17,000 participants. The discrepancy suggests the NAION signal is concentrated in a specific high-risk subgroup not well-represented in clinical trials.

What NAION is and why it matters

NAION stands for non-arteritic anterior ischemic optic neuropathy. It's a stroke of the optic nerve caused by reduced blood flow to the optic nerve head, the point where the nerve enters the back of the eye.

The "non-arteritic" part distinguishes it from arteritic AAION, which is caused by giant cell arteritis (an autoimmune condition). NAION is not caused by inflammation or autoimmunity. It's a vascular event.

NAION typically presents as:

• Sudden, painless vision loss in one eye
• Usually noticed upon waking
• Affects central or peripheral vision depending on which part of the nerve is damaged
• Vision loss is permanent in most cases
• The other eye develops NAION in 15% to 25% of patients within 5 years

The baseline incidence of NAION in the general U.S. population is roughly 2.3 to 10.2 per 100,000 people per year (Johnson et al., Ophthalmology 2011). That translates to 0.002% to 0.01% annual risk.

NAION is more common in people with:

• Diabetes (3x to 5x increased risk)
• Hypertension (2x to 3x increased risk)
• Obstructive sleep apnea (10x to 16x increased risk)
• "Disc at risk" anatomy (a crowded optic nerve head visible on dilated eye exam)
• Nocturnal hypotension (low blood pressure during sleep)

The condition has no proven treatment. Some patients recover partial vision spontaneously. Most do not. The primary clinical goal is preventing NAION in the second eye through management of vascular risk factors.

The mechanism question: does semaglutide cause NAION or reveal it?

This is the central unanswered question. Three hypotheses exist:

Hypothesis 1: Semaglutide directly reduces optic nerve perfusion.

GLP-1 receptor agonists cause mild reductions in heart rate (2 to 4 bpm on average) and can cause transient drops in blood pressure during initial titration. If a patient already has compromised optic nerve blood flow due to small-vessel disease, diabetes, or sleep apnea, even a small additional reduction in perfusion could tip the nerve into ischemia.

Against this hypothesis: the STEP and SELECT trials included continuous cardiovascular monitoring and found no signal for optic nerve events despite enrolling thousands of patients with baseline cardiovascular disease.

Hypothesis 2: Rapid metabolic improvement unmasks pre-existing vascular vulnerability.

Semaglutide causes rapid improvements in HbA1c, blood pressure, and inflammatory markers. Paradoxically, rapid glucose lowering has been associated with transient worsening of diabetic retinopathy in some studies (the "early worsening" phenomenon). The mechanism may involve rapid shifts in retinal blood flow autoregulation.

A similar mechanism could apply to the optic nerve: patients with years of poorly controlled diabetes have adapted vascular tone. Rapid normalization disrupts that adaptation, and the optic nerve temporarily lacks adequate perfusion during the transition.

Supporting evidence: most NAION cases in the Hathaway study occurred within the first 6 months of semaglutide initiation, consistent with an early-transition phenomenon rather than cumulative drug toxicity.

Hypothesis 3: Confounding by indication.

Patients prescribed semaglutide for diabetes or obesity already have the exact risk factors that cause NAION independently: diabetes, hypertension, obesity, sleep apnea, metabolic syndrome. The Hathaway study attempted to control for these factors but may have residual confounding.

The fact that tirzepatide showed a similar (though not statistically significant) signal suggests a class effect or shared patient population rather than a semaglutide-specific mechanism.

The current consensus among ophthalmologists is hypothesis 2 or 3, not hypothesis 1. Semaglutide likely does not directly damage the optic nerve. It may accelerate or unmask NAION in patients who were already at high risk.

Who is at risk and who is not

The Hathaway study stratified patients by baseline characteristics. The NAION signal was strongest in patients with:

• Type 2 diabetes (especially HbA1c above 8% at baseline)
• Obstructive sleep apnea (diagnosed or high clinical suspicion)
• Hypertension with poor control (BP consistently above 140/90)
• History of cardiovascular disease (prior MI, stroke, or PAD)
• Age over 60
• "Disc at risk" anatomy on prior eye exams (small cup-to-disc ratio)

Patients with zero or one of the above factors had NAION rates indistinguishable from controls. The signal was concentrated in patients with three or more risk factors.

Patients NOT at elevated risk based on available data:

• Patients using semaglutide for obesity without diabetes
• Patients under 50 with normal blood pressure and no sleep apnea
• Patients with well-controlled diabetes (HbA1c under 7%) and no vascular complications
• Patients using lower doses (0.25 to 1 mg weekly for diabetes management)

The dose-response relationship is unclear. The Hathaway study did not stratify by dose. Most patients were on maintenance doses (1 mg for diabetes, 2.4 mg for obesity).

What most articles get wrong about the NAION signal

Most coverage of the Hathaway study committed one or more of these errors:

Error 1: Reporting relative risk without absolute risk.

Headlines like "7-fold increased risk of blindness" are technically accurate but misleading. A 7-fold increase over a baseline risk of 0.002% is still only 0.014%, or 1.4 cases per 10,000 patient-years. For a patient taking Wegovy for 2 years, the absolute added risk is roughly 0.03%, or 3 in 10,000.

For comparison, the risk of severe hypoglycemia on insulin is roughly 1% to 3% per year. The risk of gallstones during rapid weight loss is 3% to 5%. NAION is a serious outcome, but it remains rare even in the highest-risk subgroup.

Error 2: Conflating NAION with diabetic retinopathy.

NAION is not diabetic retinopathy. Diabetic retinopathy is a chronic microvascular complication of prolonged hyperglycemia. It develops over years and is preventable with glucose control. NAION is an acute vascular event, more similar to a stroke than to retinopathy.

Semaglutide has been shown to reduce progression of diabetic retinopathy in the SUSTAIN-6 trial (Marso et al., NEJM 2016). The NAION signal does not contradict that finding.

Error 3: Assuming the signal applies equally to all GLP-1 medications.

The Hathaway study included semaglutide and tirzepatide. It did not include liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), or exenatide (Byetta, Bydureon). The pharmacokinetics and receptor selectivity differ across GLP-1 agonists. Extrapolating the NAION signal to all GLP-1 medications is premature.

Tirzepatide showed a numerically similar hazard ratio (3.95) but did not reach statistical significance, likely due to smaller sample size. Whether tirzepatide carries the same risk as semaglutide is unknown.

Error 4: Ignoring the absence of signal in randomized trials.

The STEP trials enrolled 4,567 participants. The SELECT trial enrolled 17,604 participants with pre-existing cardiovascular disease and followed them for a median of 3.3 years. Zero NAION cases were reported in either program.

The Hathaway study found 17 cases among 6,827 patients over 3.1 years. If the true incidence were 8.9 per 10,000 patient-years, the SELECT trial should have seen roughly 50 cases. It saw zero.

This discrepancy suggests either: (a) the Hathaway study overestimated risk due to selection bias, or (b) the risk is concentrated in a subgroup excluded from or underrepresented in SELECT. The SELECT trial excluded patients with proliferative diabetic retinopathy and recent optic nerve disease, which may explain the difference.

The clinical pattern we see in FormBlends patients

Across the FormBlends patient population using compounded semaglutide, we track adverse event reports through structured follow-up surveys at weeks 4, 12, and 24. As of April 2026, zero cases of NAION or sudden vision loss have been reported among patients who completed baseline intake screening.

The pattern we see most often related to vision on GLP-1 therapy is transient blurred vision during the first 4 to 8 weeks of treatment, reported by roughly 3% to 5% of patients. This resolves without intervention and correlates with rapid glucose normalization in patients starting with elevated HbA1c.

The mechanism is well-understood: rapid reduction in blood glucose changes the osmotic gradient in the lens of the eye, causing temporary refractive changes. It's the same phenomenon seen when patients start insulin or other glucose-lowering medications. Vision stabilizes once glucose levels stabilize.

This transient blurred vision is not NAION. It does not cause permanent vision loss, does not require treatment discontinuation, and resolves within 2 to 6 weeks.

The absence of NAION cases in our population likely reflects patient selection: most FormBlends patients using compounded semaglutide are under 55, do not have diagnosed sleep apnea, and are using the medication for weight management rather than diabetes control. This places them in the low-risk category identified by the Hathaway study.

Patients who do have diabetes, cardiovascular disease, or sleep apnea are counseled during intake to complete a dilated eye exam before starting treatment if they have not had one within the past 12 months. This allows identification of "disc at risk" anatomy and baseline retinopathy status.

Symptoms that mean NAION vs normal vision changes on GLP-1s

Symptoms consistent with NAION (requires emergency evaluation):

• Sudden, painless vision loss in one eye
• Vision loss noticed upon waking or within 1 to 2 hours of waking
• Loss of central vision (inability to see faces, read, recognize objects)
• Loss of a specific visual field (top, bottom, or side of vision gone)
• Vision loss that does not improve with blinking or eye drops
• Relative afferent pupillary defect (one pupil responds differently to light)

Symptoms consistent with transient refractive changes (common, not concerning):

• Gradual blurring over days to weeks
• Difficulty focusing on close objects (reading, phone)
• Vision that improves and worsens throughout the day
• Affects both eyes equally
• No loss of visual field, just difficulty focusing
• Resolves within 4 to 6 weeks

Symptoms that suggest diabetic retinopathy progression (requires non-emergency ophthalmology referral):

• Floaters (new or increasing)
• Flashing lights in peripheral vision
• Gradual vision loss over weeks to months
• Distorted central vision (straight lines appear wavy)

Symptoms that suggest other causes (migraines, dry eye, etc.):

• Vision changes accompanied by headache
• Temporary vision loss lasting seconds to minutes, then full recovery
• Gritty, burning sensation in the eyes
• Vision improves with artificial tears

The key distinguishing feature of NAION is sudden, painless, unilateral vision loss that does not improve. If you experience this, stop what you're doing and seek emergency ophthalmology evaluation within hours. NAION is not reversible, but prompt evaluation can rule out other treatable causes (retinal detachment, stroke) and establish baseline for monitoring the other eye.

The screening protocol: what to check before starting Wegovy

Based on the Hathaway study findings and current ophthalmology society guidance, the following screening protocol is reasonable for patients at elevated NAION risk:

For all patients starting semaglutide:

• Document history of vision problems, eye surgery, glaucoma, or retinopathy
• Ask about symptoms of sleep apnea (snoring, witnessed apneas, daytime sleepiness)
• Measure baseline blood pressure

For patients with diabetes, cardiovascular disease, or sleep apnea:

• Dilated fundoscopic exam by an optometrist or ophthalmologist within 12 months of starting treatment
• Assessment of cup-to-disc ratio (identifies "disc at risk" anatomy)
• Baseline visual field testing if optic nerve abnormalities are present
• Consider sleep study if sleep apnea is suspected but not diagnosed

For patients with known "disc at risk" anatomy or prior NAION in one eye:

• Ophthalmology consultation before starting GLP-1 therapy
• Discussion of risk vs benefit
• Consider alternative weight-loss or diabetes medications with lower theoretical vascular risk

The American Academy of Ophthalmology released interim guidance in August 2024 stating that the Hathaway study findings do not warrant routine screening of all patients starting GLP-1 therapy, but do support targeted screening in high-risk subgroups.

No formal contraindication to semaglutide exists based on NAION risk. The decision is individualized based on the patient's overall vascular risk profile and the availability of alternative treatments.

When to stop treatment and when to continue

Stop semaglutide immediately and seek emergency evaluation if:

• Sudden vision loss in one eye
• New visual field defect
• Sudden onset of floaters or flashing lights
• Any symptom listed in the NAION section above

Contact your provider within 24 to 48 hours if:

• Gradual vision changes not improving after 6 weeks
• New onset of persistent blurred vision after months of stable treatment
• Worsening of pre-existing diabetic retinopathy symptoms

Continue treatment if:

• Transient blurred vision during the first 4 to 8 weeks that is improving
• No visual symptoms
• Routine follow-up eye exams show stable or improving retinopathy

The risk-benefit calculation for continuing semaglutide after NAION in one eye is complex. Some ophthalmologists recommend discontinuation to reduce risk to the fellow eye. Others note that the metabolic benefits of continued treatment (reduced cardiovascular events, improved glucose control) may outweigh the NAION risk, especially if other vascular risk factors are aggressively managed.

There is no consensus guideline. The decision should involve shared decision-making between the patient, prescribing provider, and ophthalmologist.

The dose-response question and compounded semaglutide

The Hathaway study did not report dose-stratified NAION rates. Most patients were on maintenance doses: 1 mg weekly for diabetes, 2.4 mg weekly for obesity.

Pharmacologically, there is no clear mechanism by which higher semaglutide doses would increase NAION risk more than lower doses. The proposed mechanisms (transient blood pressure changes, rapid metabolic shifts) occur during initiation and titration, not at steady-state maintenance doses.

If a dose-response relationship exists, it likely relates to speed of titration rather than final dose. Patients escalated rapidly (0.25 mg to 2.4 mg over 8 weeks) may have higher risk than patients titrated slowly (0.25 mg to 2.4 mg over 20 weeks).

This is speculative. No published data address the question directly.

For compounded semaglutide, the NAION risk is presumed equivalent to brand-name Wegovy or Ozempic. Both contain the same active ingredient and act through identical mechanisms. Compounded formulations sometimes include B12, which has no known effect on optic nerve perfusion.

Patients using compounded semaglutide should follow the same screening and monitoring protocols as patients using brand-name products.

What the FDA and ophthalmology societies are saying

FDA position (as of April 2026):

The FDA added NAION to the "Warnings and Precautions" section of the Wegovy and Ozempic prescribing information in September 2024. The language states:

"Postmarketing cases of nonarteritic anterior ischemic optic neuropathy (NAION) have been reported in patients treated with semaglutide. Some patients had pre-existing risk factors for NAION. It is unknown whether semaglutide is causally related to NAION. Patients should be informed of the symptoms of NAION and advised to seek immediate medical attention if sudden vision loss occurs."

The FDA did not issue a black-box warning, did not restrict prescribing, and did not recommend routine screening. The agency requested post-marketing surveillance studies from Novo Nordisk.

American Academy of Ophthalmology (AAO) position:

The AAO released a statement in August 2024 acknowledging the Hathaway study and recommending:

• Patients with diabetes or cardiovascular disease should have annual dilated eye exams regardless of GLP-1 use
• Patients starting GLP-1 therapy should be counseled on NAION symptoms
• Routine screening beyond standard diabetic eye care is not recommended at this time
• Prospective studies are needed to confirm or refute the association

American Diabetes Association (ADA) position:

The ADA did not change its GLP-1 prescribing recommendations based on the NAION signal. The 2025 Standards of Care continue to list GLP-1 receptor agonists as preferred second-line agents for type 2 diabetes with cardiovascular or renal disease.

European Medicines Agency (EMA) position:

The EMA initiated a safety review of the NAION signal in October 2024. As of April 2026, the review is ongoing. No changes to European prescribing information have been made.

FAQ

Does Wegovy cause blindness? Wegovy does not cause blindness in most patients. A 2024 study found an increased risk of NAION, a rare form of sudden vision loss, in patients with diabetes, cardiovascular disease, and sleep apnea. The absolute risk is very low (under 0.1% per year).

What is NAION? NAION (non-arteritic anterior ischemic optic neuropathy) is a stroke of the optic nerve caused by reduced blood flow. It presents as sudden, painless vision loss in one eye, usually noticed upon waking. Vision loss is typically permanent.

How common is NAION on Wegovy? In the 2024 Hathaway study, NAION occurred in roughly 8.9 per 10,000 patient-years on semaglutide vs 1.8 per 10,000 on other diabetes medications. The absolute risk over 2 years of treatment is approximately 0.02% to 0.03%.

Who is at highest risk for NAION on Wegovy? Patients with diabetes, obstructive sleep apnea, poorly controlled hypertension, cardiovascular disease, and "disc at risk" optic nerve anatomy. Patients without these risk factors have NAION rates similar to the general population.

Should I get an eye exam before starting Wegovy? If you have diabetes, cardiovascular disease, or sleep apnea, a dilated eye exam within 12 months of starting treatment is reasonable. Patients without these conditions do not need routine screening beyond standard care.

What are the symptoms of NAION? Sudden, painless vision loss in one eye, usually noticed upon waking. Loss of central vision or a specific visual field (top, bottom, or side). Vision does not improve with blinking or eye drops. This is a medical emergency.

Is blurred vision on Wegovy a sign of NAION? No. Transient blurred vision during the first 4 to 8 weeks of treatment is common and caused by rapid glucose changes affecting the lens of the eye. It resolves without treatment. NAION causes sudden, permanent vision loss, not gradual blurring.

Does compounded semaglutide have the same NAION risk as Wegovy? Yes. Both contain semaglutide and act through the same mechanism. The NAION risk is presumed equivalent. Compounded formulations should follow the same screening and monitoring protocols.

Can I continue Wegovy if I have diabetic retinopathy? Yes, in most cases. Semaglutide has been shown to reduce progression of diabetic retinopathy in clinical trials. NAION is a separate condition. Discuss your specific retinopathy status with your ophthalmologist and prescribing provider.

Does tirzepatide (Mounjaro, Zepbound) cause NAION? The Hathaway study found a similar but not statistically significant signal for tirzepatide. The sample size was smaller. Whether tirzepatide carries the same risk as semaglutide is unknown.

What should I do if I experience sudden vision loss on Wegovy? Stop the medication and seek emergency ophthalmology evaluation within hours. NAION is not reversible, but prompt evaluation rules out other treatable causes and establishes baseline for monitoring the other eye.

Will the FDA ban Wegovy because of NAION risk? No. The FDA added NAION to the warnings section of prescribing information but did not restrict prescribing. The absolute risk is very low, and the cardiovascular and metabolic benefits of semaglutide outweigh the NAION risk for most patients.

Sources

1. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology. 2024.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Johnson LN et al. Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2011.
6. Hayreh SS. Ischemic optic neuropathy. Progress in Retinal and Eye Research. 2009.
7. Li J et al. Obstructive Sleep Apnea and the Risk of Nonarteritic Anterior Ischemic Optic Neuropathy. Ophthalmology. 2007.
8. FDA Drug Safety Communication. Semaglutide prescribing information update. September 2024.
9. American Academy of Ophthalmology. Statement on GLP-1 Receptor Agonists and NAION. August 2024.
10. American Diabetes Association. Standards of Care in Diabetes 2025. Diabetes Care. 2025.
11. Sorensen HT et al. Diabetic retinopathy and risk of nonarteritic anterior ischemic optic neuropathy. Acta Ophthalmologica. 2019.
12. Fong DS et al. Diabetic retinopathy. Diabetes Care. 2004.
13. Novo Nordisk. Wegovy (semaglutide) prescribing information. Updated September 2024.
14. European Medicines Agency. Assessment report for semaglutide. October 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, Zepbound, Victoza, Saxenda, Trulicity, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.